CAJ | 학술논문

目的：探讨高心血管选择性β受体阻断药比索洛尔对病情稳定的COPD致肺源性心脏病患者心率变异性（ HRV）的影响。方法选择2011年1月至2012年7月治疗稳定的COPD致肺源性心脏病患者36例。患者在规范的COPD、肺源性心脏病及其合并症治疗基础上，加用比索乐尔2.5 mg，随访4周，研究前后所有患者均行动态心电图及FEV1检查。结果与研究前比较，研究结束时，患者HRV明显改善，差异有统计学意义（ P＜0.05）；患者治疗前后FEV1比较，差异无统计学意义（ P＞0.05）。结论比索洛尔能改善病情稳定的COPD致肺源性心脏病患者HRV。
목적：탐토고심혈관선택성β수체조단약비색락이대병정은정적COPD치폐원성심장병환자심솔변이성（ HRV）적영향。방법선택2011년1월지2012년7월치료은정적COPD치폐원성심장병환자36례。환자재규범적COPD、폐원성심장병급기합병증치료기출상，가용비색악이2.5 mg，수방4주，연구전후소유환자균행동태심전도급FEV1검사。결과여연구전비교，연구결속시，환자HRV명현개선，차이유통계학의의（ P＜0.05）；환자치료전후FEV1비교，차이무통계학의의（ P＞0.05）。결론비색락이능개선병정은정적COPD치폐원성심장병환자HRV。
Objective To investigate the effect of high cardiovascular-selective β-blocker bisoprolol on heart rate variability (HRV) in patients with stable pulmonary heart disease (PHD) induced by chronic obstructive pulmonary disease ( COPD).Methods A total of 36 patients with stable PHD induced by COPD were recruited in this study from 2011.1 to 2012.7.All patients were administrated with bisoprolol (2.5mg, once daily) on the basis of standard treatment to PHD , COPD and the concomitant diseases.All subjects were followed up for 4 weeks.The HRV and forced expiratory volume in the first second (FEV1) were examined in all subjects at enrollment and at the end of study.Results In comparison with the levels at enrollment , the levels of HRV at the end of study were significantly improved , P<0.05.There were no significant differences on FEV1 between the levels at the beginning and end of study , P>0.05.Conclusion The levels of HRV might be improve by Bisoprolol in patients with stable PHD induced by COPD.